Recursion Pharmaceuticals, Inc. (RXRX)
NASDAQ · Healthcare
Recursion Pharmaceuticals, Inc. Operating Income 2019–2025
Recursion Pharmaceuticals, Inc. annual/quarterly operating income history and growth rate from 2019 to 2026. Operating income (EBIT) is profit from core business operations, excluding interest and income taxes. It reflects the efficiency of a company's core operations.
- Recursion Pharmaceuticals, Inc. operating income for the quarter ending March 31, 2026 was -128.5 M, a 32.85% decrease year-over-year.
- Recursion Pharmaceuticals, Inc. operating income for the twelve months ending March 31, 2026 was -668.3 M, a 69.28% increase year-over-year.
- Recursion Pharmaceuticals, Inc. annual operating income for 2025 was -648.1 M, a 35.31% increase from 2024.
- Recursion Pharmaceuticals, Inc. annual operating income for 2024 was -479.0 M, a 36.83% increase from 2023.
- Recursion Pharmaceuticals, Inc. annual operating income for 2023 was -350.1 M, a 42.46% increase from 2022.
- Recursion Pharmaceuticals, Inc. annual operating income for 2022 was -245.7 M.
Operating Income
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Recursion Pharmaceuticals, Inc. Operating Income — FAQ
Recursion Pharmaceuticals, Inc. (RXRX) operating income over the last 7 years — annual and quarterly figures with year-over-year growth and charts.
What is Recursion Pharmaceuticals, Inc.'s operating income?
Recursion Pharmaceuticals, Inc. (RXRX) reported operating income of -$648M for fiscal 2025.
Where can I see RXRX's operating income history?
The chart and table above show Recursion Pharmaceuticals, Inc.'s operating income by year and by quarter, including the growth rate.